Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inhibition of CDK Activity02:34

Inhibition of CDK Activity

5.6K
5.6K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

6.2K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

4.2K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
4.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Signaling Mutations Negate the Favorable Impact of NPM1 Mutations in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With VEN/HMA.

American journal of hematology·2026
Same author

Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax-an analysis from the International Consortium for MDS (icMDS) VALIDATE database.

Blood cancer journal·2026
Same author

Outcomes of Adolescents and Young Adults with AML Treated on Pediatric vs Adult Protocols.

Blood advances·2026
Same author

Detection of MEN1 resistance mutations in cell-free DNA from acute leukemia patients treated with menin inhibitors.

Blood cancer journal·2026
Same author

Lorlatinib-induced remission in refractory acute myeloid leukemia with an anaplastic lymphoma kinase fusion.

Haematologica·2026

Related Experiment Video

Updated: Mar 29, 2026

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
04:36

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on: October 17, 2025

1.1K

IDH2 inhibition in AML: Finally progress?

Eytan M Stein1

  • 1Leukemia Service, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, 1275 York Avenue, New York, NY 10065, USA.

Best Practice & Research. Clinical Haematology
|November 23, 2015
PubMed
Summary

Mutations in isocitrate dehydrogenase (IDH) enzymes are linked to acute myeloid leukemia (AML). This review discusses IDH mutations and the potential of the inhibitor AG-221 for treating mutant IDH2.

Keywords:
2-HGAcute myeloid leukemiaIsocitrate dehydrogenase

More Related Videos

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.8K
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

909

Related Experiment Videos

Last Updated: Mar 29, 2026

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
04:36

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on: October 17, 2025

1.1K
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.8K
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

909

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • Isocitrate dehydrogenase (IDH) is a key enzyme in cellular metabolism, catalyzing the conversion of isocitrate to alpha-ketoglutarate.
  • IDH exists in three isoforms (IDH1, IDH2, IDH3), with distinct cellular localizations and functions.
  • Specific mutations in IDH1 (R132) and IDH2 (R172, R140) are frequently observed in certain cancers, including acute myeloid leukemia (AML).

Purpose of the Study:

  • To review the significance of IDH mutations in the pathogenesis of acute myeloid leukemia (AML).
  • To discuss the therapeutic potential of targeting mutant IDH2, specifically with the inhibitor AG-221.

Main Methods:

  • Literature review of studies investigating IDH mutations and their role in AML.
  • Analysis of preclinical and early clinical data on the efficacy of AG-221 in inhibiting mutant IDH2.

Main Results:

  • Mutations in IDH1 and IDH2, particularly at specific residues, are prevalent in AML cases.
  • The reversible inhibitor AG-221 shows early promise in targeting and inhibiting mutant IDH2.

Conclusions:

  • IDH mutations represent a critical factor in AML development and progression.
  • Targeted inhibition of mutant IDH2 with agents like AG-221 offers a potential therapeutic strategy for AML patients with these mutations.